Leica Biosystems acquires StatLab Medical Products
The deal adds a 50-year-old histology consumables portfolio to Leica’s pathology and AI-diagnostics platform, backed by Danaher.
Takeaways
- StatLab Medical Products is a Developer and manufacturer of anatomical pathology products for histology workflow laboratories.
- Audax Private Equity and Linden Capital Partners is exiting StatLab Medical Products through a sale to Leica Biosystems.
StatLab Medical Products, a developer of anatomical pathology consumables for histology labs, is being acquired by Leica Biosystems from its private equity sponsors Audax Private Equity and Linden Capital Partners.
For more than 50 years, the company has supplied products spanning the histology workflow from specimen collection and tissue processing through slide preparation and staining.
Upon closing, StatLab will be integrated as part of Leica Biosystems, a Danaher operating company focused on anatomic pathology and AI-enabled diagnostics.
"We are excited by the opportunity to combine StatLab's trusted portfolio with Leica Biosystems' global leadership in pathology, computational pathology and AI-enabled diagnostics.
Together, we can solve some of the hardest problems in healthcare by helping laboratories achieve the consistency, standardization, and quality required to adopt AI-enabled cancer diagnostics at scale," said Gustavo Perez Fernandez, Group Executive, Danaher's Diagnostics business, and President, Leica Biosystems.
Get Buyout Desk email updates.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up on the site. Email updates are not on a fixed schedule.